Jonas P. Koch

Jonas P. Koch

Auto-generated profile, based on publicly available information

Jonas P. Koch

Department of Radiation Oncology, Inselspital Bern University Hospital, Bern, Switzerland. 1

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2023 in iScience
Verified
Journal Article
Open access
JKJonas Koch
Jonas Koch
MNManuel Neuberger
Manuel Neuberger
Martina SchmidtMartina Schmidt
Martina Schmidt
JXJinyun Xu
Jinyun Xu
VCVitor Coutinho Carneiro
Vitor Coutinho Carneiro
Frank LykoFrank Lyko
Frank Lyko
METTL3 is the major writer of N6-Methyladenosine (m6A) and has been associated with controversial roles in cancer. This is best illustrated in urothelial carcinoma of the bladder (UCB), where METTL3 was described to have both oncogenic and tumor-suppressive functions. Here, we reinvestigated the role of METTL3 in UCB. METTL3 knockout reduced the oncogenic phenotype and m6A levels of UCB cell lines. However, complete depletion of METTL3/m6A was not achieved due to selection of cells expressing alternative METTL3 isoforms. Systematic vulnerability and inhibitor response analyses suggested that uroepithelial cells depend on METTL3 for viability. Furthermore, expression and survival analyses of clinical data revealed a complex role for METTL3 in UCB, with decreased m6A mRNA levels in UCB tumors. Our results suggest that METTL3 expression may be a suitable diagnostic UCB biomarker, as the enzyme promotes UCB formation. However, the suitability of the enzyme as a therapeutic target should be evaluated carefully.

1 July 2024 in Cancer Research Communications
Verified
Journal Article
Open access
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
Various lines of investigation support a signaling interphase shared by receptor tyrosine kinases and the DNA damage response. However, the underlying network nodes and their contribution to the maintenance of DNA integrity remain unknown. We explored MET-related metabolic pathways in which interruption compromises proper resolution of DNA damage. Discovery metabolomics combined with transcriptomics identified changes in pathways relevant to DNA repair following MET inhibition (METi). METi by tepotinib was associated with the formation of γH2AX foci and with significant alterations in major metabolic circuits such as glycolysis, gluconeogenesis, and purine, pyrimidine, amino acid, and lipid metabolism. 5′-Phosphoribosyl-N-formylglycinamide, a de novo purine synthesis pathway metabolite, was consistently decreased in in vitro and in vivo MET-dependent models, and METi-related depletion of dNTPs was observed. METi instigated the downregulation of critical purine synthesis enzymes including phosphoribosylglycinamide formyltransferase, which catalyzes 5′-phosphoribosyl-N-formylglycinamide synthesis. Genes encoding these enzymes are regulated through E2F1, whose levels decrease upon METi in MET-driven cells and xenografts. Transient E2F1 overexpression prevented dNTP depletion and the concomitant METi-associated DNA damage in MET-driven cells. We conclude that DNA damage following METi results from dNTP reduction via downregulation of E2F1 and a consequent decline of de novo purine synthesis. Significance: Maintenance of genome stability prevents disease and affiliates with growth factor receptor tyrosine kinases. We identified de novo purine synthesis as a pathway in which key enzymatic players are regulated through MET receptor and whose depletion via MET targeting explains MET inhibition-associated formation of DNA double-strand breaks. The mechanistic importance of MET inhibition-dependent E2F1 downregulation for interference with DNA integrity has translational implications for MET-targeting-based treatment of malignancies.

15 May 2023 in Oncogene
Verified
Journal Article
Open access
PDF file
JKJonas P. Koch
Jonas P. Koch
SRSelina M. Roth
Selina M. Roth
AQAurélie Quintin
Aurélie Quintin
JGJacopo Gavini
Jacopo Gavini
EOEleonora Orlando
Eleonora Orlando
MMMichaela Medova
Michaela Medova
The DNA damage response (DDR) is intertwined with signaling pathways downstream of oncogenic receptor tyrosine kinases (RTKs). To drive research into the application of targeted therapies as radiosensitizers, a better understanding of this molecular crosstalk is necessary. We present here the characterization of a previously unreported MET RTK phosphosite, Serine 1016 (S1016) that represents a potential DDR-MET interface. MET S1016 phosphorylation increases in response to irradiation and is mainly targeted by DNA-dependent protein kinase (DNA-PK). Phosphoproteomics unveils an impact of the S1016A substitution on the overall long-term cell cycle regulation following DNA damage. Accordingly, the abrogation of this phosphosite strongly perturbs the phosphorylation of proteins involved in the cell cycle and formation of the mitotic spindle, enabling cells to bypass a G2 arrest upon irradiation and leading to the entry into mitosis despite compromised genome integrity. This results in the formation of abnormal mitotic spindles and a lower proliferation rate. Altogether, the current data uncover a novel signaling mechanism through which the DDR uses a growth factor receptor system for regulating and maintaining genome stability.

30 July 2024
Verified
Other
Open access
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
Summary of the significance analysis for the survival analyses.

30 July 2024
Verified
Other
Open access
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
Therapeutic implications of the MET-E2F1-purine synthesis pathway as a component of the MET-DDR crosstalk. A, Proliferation of EBC-1 and HCC827 cells upon treatments with the indicated doses of tepotinib, cisplatin, and their combination assessed by crystal violet assay 72 hours posttreatment. Data points are represented as mean ± SD of technical replicates (dots). Statistical analyses were done using one-way ANOVA. B, Schematic representation of the proposed MET-E2F1-purine synthesis pathway and its interplay with the DDR in MET-driven cancer cells. MET inhibition by the small-molecule inhibitor tepotinib downregulates E2F1 via the MAPK pathway, consequently downregulating purine synthesis enzymes (e.g., GART) and RNR. This leads to the depletion of dNTPs, compromising the ability of cells to repair DNA damage. Created with BioRender.com.

17 September 2024
Verified
Other
Open access
PDF file
MTMichaela Poliaková Turan
Michaela Poliaková Turan
RRRahel Riedo
Rahel Riedo
MMMatúš Medo
Matúš Medo
CPChiara Pozzato
Chiara Pozzato
MFManja Friese-Hamim
Manja Friese-Hamim
MMMichaela Medova
Michaela Medova
Supplementations with glutamine, serine, and folic acid: (A) Proliferation of GTL-16 and EBC-1 cells upon supplementation with glutamine, serine or folic acid. (B) Apoptosis (caspase-3 activation) in GTL-16 and EBC-1 cells upon supplementation with glutamine, serine or folic acid.